Monday, September 23, 2019
STALICLA to present at the SACHS Associates Biotech in Europe Forum, Basel - September 25-26
CEO, Lynn Durham, will represent STALICLA at the 19thAnnual Biotech in Europe Forum. Lynn will be speaking on day 1, with a company presentation (14:00 – 14:15 CET, 25thSeptember) and as a Panellist on the Neurosciences Panel 1 (16:05 – 16:55 CET, 25thSeptember).
“I am looking forward to joining our peers in the industry at SACH’S again this year and taking part in the Neurosciences panel discussion. Our company presentation will include up-coming clinical milestones for our precision medicine treatment (STP1) for Autism Spectrum Disorder and key information on the expansion of STALICLA’s unique drug discovery platform, DEPI,”
said Lynn Durham.
DEPI is an integrative framework that uses large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and identify personalized treatments. As part of its on-going development, DEPI offers a broad potential and can be extended to other complex brain disorders.
The SACHS Biotech in Europe Forum, which takes place in Basel, is recognised as a leading international stage for Biotechs and Investors in the life science industry. For more information go to:
Please direct investor or media enquiries during the event to:
0041 (0) 22 545 12 42